MiR-223-5p works as an oncomiR in vulvar carcinoma by TP63 suppression

• Autor(a) principal: Maia, Beatriz de Melo
• Data de Publicação: 2016
• Outros Autores: Rodrigues, Iara Santana, Akagi, Erica Mie, do Amaral, Nayra Soares, Ling, Hui, Monroig, Paloma, Soares, Fernando Augusto, Calin, George Adrian, Rocha, Rafael Malagoli [UNIFESP]
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Repositório Institucional da UNIFESP
• Texto Completo: http://dx.doi.org/10.18632/oncotarget.10247; http://repositorio.unifesp.br/handle/11600/51176
• topic: vulvar cancer; microRNAs; cellular assays; hsa-miR-223-5p; TP63

MiR-223-5p has been previously mentioned to be associated with tumor metastasis in HPV negative vulvar carcinomas, such as in several other tumor types. In the present study, we hypothesized that this microRNA would be important in vulvar cancer carcinogenesis and progression. To investigate this, we artificially mimicked miR-223-5p expression in a cell line derived from lymph node metastasis of vulvar carcinoma (SW962) and performed in vitro assays. As results, lower cell proliferation (p < 0.01) and migration (p < 0.001) were observed when miR-223-5p was overexpressed. In contrast, increased invasive potential of these cells was verified (p < 0.004). In silico search indicated that miR-223-5p targets TP63, member of the TP53 family of proteins, largely described with importance in vulvar cancer. We experimentally demonstrated that this microRNA is capable to decrease levels of p63 at both mRNA and protein levels (p < 0.001, and p < 0.0001